• 1
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 2008; 54: 30314.
  • 2
    Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 2007; 178: 231430.
  • 3
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 2000; 163: 11249.
  • 4
    Highshaw RA, Tanaka ST, Evans CP, deVere White RW. Is bladder biopsy necessary at three or six months post BCG therapy? Urol. Oncol. 2003; 21: 2079.
  • 5
    Skemp NM, Fernandes ET. Routine bladder biopsy after bacille Calmette-Guerin treatment: is it necessary? Urology 2002; 59: 2246.
  • 6
    Guy L, Savareux L, Molinie V, Botto H, Boiteux JP, Lebret T. Should bladder biopsies be performed routinely after bacillus Calmette-Guerin treatment for high-risk superficial transitional cell cancer of the bladder? Eur. Urol. 2006; 50: 51620; discussion 520.
  • 7
    Dalbagni G, Rechtschaffen T, Herr HW. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy? J. Urol. 1999; 162: 7089.
  • 8
    Murakami T, Ebara S, Saika T et al. Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus calmette-guerin therapy. Acta Med. Okayama 2007; 61: 3414.
  • 9
    Nepple KG, Joudi FN, O'Donnell MA. Review of topical treatment of upper tract urothelial carcinoma. Adv. Urol. 2009; 2009: Article ID 472831.
  • 10
    Hara T, Takahashi M, Gondo T et al. Discrepancies between cytology, cystoscopy and biopsy in bladder cancer detection after Bacille Calmette-Guerin intravesical therapy. Int. J. Urol. 2009; 16: 1925.
  • 11
    May F, Treiber U, Hartung R, Schwaibold H. Significance of random bladder biopsies in superficial bladder cancer. Eur. Urol. 2003; 44: 4750.
  • 12
    van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur. Urol. 1999; 35: 26771.
  • 13
    Solsona E, Iborra I, Ricos JV, Dumont R, Casanova JL, Calabuig C. Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): its impact on management. Urology 1997; 49: 34752.
  • 14
    Witjes JA. Bladder carcinoma in situ in 2003: state of the art. Eur. Urol. 2004; 45: 1426.
  • 15
    O'Donnell MA, Boehle A. Treatment options for BCG failures. World J. Urol. 2006; 24: 4817.
  • 16
    Witjes JA, Kiemeney LA, Schaafsma HE, Debruyn FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group. Br. J. Urol. 1994; 73: 1726.